FDA Alignment to Advance ProstACT Global Phase 3 Trial
Telix today announced the successful outcome of a Type B meeting with the United States (U.S.) Food and Drug Administration (FDA) to review the Part 1 safety and dosimetry…
Read moreNews & Views
Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions
Telix today announces an educational webinar exploring the unmet needs in neurologic oncology (specifically glioma and glioblastoma) and how theranostics may help address…
Read more
Telix and United Imaging Announce Strategic Theranostics Collaboration
Telix and United Imaging Healthcare North America, Inc. (“United Imaging”) today announce the signing of a Memorandum of Understanding (MOU) to evaluate a strategic research collaboration in the United States…
Read more
ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026
Telix announces the oral presentation of Part 1 safety, dosimetry and pharmacokinetics data from the ProstACT Global Phase 3 Study of TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan), in metastatic castration-resistant prostate…
Read more
Everybody has a Superhero
News,
Craig Stankiewicz is a husband, father and business professional from Chicago, Illinois. In August 2021, Craig was diagnosed with glioblastoma (GBM) and almost five years on he continues to face…
Read more
Telix at ASCO 2026
News,
Join Telix at the 2026 ASCO Annual Meeting, taking place this week in Chicago. ASCO 2026 will feature a late-breaking oral presentation on safety and dosimetry results from Part 1 of…
Read more
Telix at SNMMI 2026
News,
Telix is in Los Angeles this week for the SNMMI 2026 Annual Meeting. This year’s program features seven abstracts from across Telix’s oncology portfolio, including three oral presentations exploring novel…
Read more
Telix to Participate in William Blair Growth Stock and Jefferies Global Healthcare Conferences
News,
Telix advises that Dr. Christian Behrenbruch, Managing Director and Group CEO, will participate in the upcoming William Blair 46th Annual Growth Stock Conference in Chicago, IL and in the Jefferies…
Read more
Fighting for Every Day
News,
Courtney Watson is the Director of Programs and Communications at Head for the Cure, a nonprofit organization dedicated to raising awareness and funding for the brain tumor community. Her mother,…
Read more
IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing
News,
Telix today announces that the IPAX-2 study[1] of TLX101-Tx (¹³¹I-iodofalan) in patients with newly diagnosed glioblastoma has completed patient enrolment. No dose-limiting toxicities (DLTs) have been observed to date, including…
Read more